Pembrolizumab, Temozolomide and HSPPC-96 Vaccine in Newly Diagnosed Glioblastoma Post-Chemoradiation: Results from a

Byram H Ozer1, Scott M Lindhorst1, Ryan T Merrell1

  • 1Neuro-Oncology Branch, National Cancer Institute/National Institutes of Health, Bethesda, Maryland, USA (B.H.O., E.B., J.W., H.L., J.G., M.P.-P., Y.Y., C.C., K.W., E.G., T.M., T.S.A., M.R.G.); Department of Neurosurgery, Medical University of South Carolina, Charleston, South Carolina, USA (S.M.L.); Department of Neurology, NorthShore University Health System, Chicago, Illinois, USA (R.T.M., C.R.T.); Department of Neurology, Cedars-Sinai Medical Center, Los Angeles, California, USA (J.D.R.); Department of Hematology and Medical Oncology (N.G.A.) and Department of Radiation Oncology (N.R.), Orlando Regional Medical Center, Orlando, Florida, USA (N.G.A., N.R.); Department of Neurology and Neurosurgery, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA (S.K., Y.R.); Department of Neurology and Neurosurgery, Henry Ford Health System, Detroit, Michigan, USA (T.W.); Department of Neurology, University of Texas Southwestern, Dallas, Texas, USA (E.P., M.Y.); Department of Neurology/Neuro-Oncology, Baylor Scott&White, Baylor University Medical Center, Houston, Texas, USA (K.L.F.); Department of Neurology, Baylor College of Medicine, Houston, Texas, USA (J.J.M.); Department of Neurology, Alvord Brain Tumor Center, University of Washington and Fred Hutchinson Cancer Center, Seattle, Washington, USA (L.P.T.); Department of Neurosurgery, Huntsman Cancer Institute, Salt Lake City, Utah, USA (H.C.); Piedmont Brain Tumor Center, Atlanta, Georgia, USA (E.M.D.); Division of Neurology, Advocate Medical Group, Downers Grove, Illinois, USA (N.P.); Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois (J.J.R.); Department of Biostatistics, MD Anderson Cancer Center, Houston, Texas, USA (Y.Y.); Scientific Leadership and Research Manager, MSD/Merck&Co, Inc., Rahway, New Jersey, USA (E.V.); Director of Manufacturing and Logistics, Agenus, Lexington, Massachusetts, USA (S.C.).

Abstract

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...